Osteogenesis Imperfecta - Pipeline Review, H1 2017

Publisher Name :
Date: 08-Mar-2017
No. of pages: 45
Price : Single User: US $ 2000  US $ 1700 Corporate User: US $ 6000  US $ 4800
Inquire Before Buying
This report is available at 15% Discount for Single User License and 20% Discount for Corporate Users License till 01 September 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteogenesis Imperfecta - Pipeline Review, H1 2017, provides an overview of the Osteogenesis Imperfecta (Genetic Disorders) pipeline landscape.

Osteogenesis imperfecta (OI) is a genetic disorder characterized by bones that break easily, often from little or no apparent cause. This disease is caused by a defect, or flaw, in the gene that produces type 1 collagen, a protein used to create bone. Symptoms include bone deformities, multiple broken bones, loose joints, weak teeth, heart defects and respiratory problems. Treatment includes bisphosphonates and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteogenesis Imperfecta - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteogenesis Imperfecta (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteogenesis Imperfecta and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 3 respectively.

Osteogenesis Imperfecta (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note*: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteogenesis Imperfecta (Genetic Disorders).

  • The pipeline guide reviews pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Osteogenesis Imperfecta (Genetic Disorders) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Osteogenesis Imperfecta (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Osteogenesis Imperfecta (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

This report is available at 15% Discount for Single User License and 20% Discount for Corporate Users License till 01 September 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Osteogenesis Imperfecta - Pipeline Review, H1 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Osteogenesis Imperfecta - Overview
Osteogenesis Imperfecta - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Osteogenesis Imperfecta - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Osteogenesis Imperfecta - Companies Involved in Therapeutics Development
Amgen Inc
Bone Therapeutics SA
Genzyme Corp
Mereo Biopharma Group Plc
Osteogenesis Imperfecta - Drug Profiles
ALLOB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPS-804 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fresolimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAL-436/9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Osteogenesis Imperfecta - Product Development Milestones
Featured News & Press Releases
Feb 20, 2017: Mereo BioPharma: BPS-804 accepted for EMA Adaptive Pathways programme
Jun 30, 2016: Mereo's BPS-804 granted EU Orphan Drug status for Osteogenesis Imperfecta
Mar 02, 2016: Mereo BPS-804 granted U.S. orphan drug status for osteogenesis imperfecta
Oct 01, 2013: Bone Therapeutics receives clearance for ALLOB phase I/IIa trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Osteogenesis Imperfecta, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Osteogenesis Imperfecta - Pipeline by Amgen Inc, H1 2017
Osteogenesis Imperfecta - Pipeline by Bone Therapeutics SA, H1 2017
Osteogenesis Imperfecta - Pipeline by Genzyme Corp, H1 2017
Osteogenesis Imperfecta - Pipeline by Mereo Biopharma Group Plc, H1 2017

List of Figures

Number of Products under Development for Osteogenesis Imperfecta, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • United States Peptide Therapeutics Market Report 2017
    Published: 18-Aug-2017        Price: US 3800 Onwards        Pages: 98
    In this report, the United States Peptide Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rat......
  • United States Hypertrophic Cardiomyopathy Therapeutics Market Report 2017
    Published: 17-Aug-2017        Price: US 3800 Onwards        Pages: 102
    In this report, the United States Hypertrophic Cardiomyopathy Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market ......
  • Raynauds Disease - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 48
    Raynauds Disease - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Raynauds Disease - Pipeline Review, H2 2017, provides an overview of the Raynauds Disease (Cardiovascular) pipeline landscape. Raynauds disease is a common condition that affects the blood supply to certain parts of the body, usually the fingers and toes. Predisposing factors include age, gender, family history and smok......
  • Batten Disease - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 53
    Batten Disease - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Batten Disease - Pipeline Review, H2 2017, provides an overview of the Batten Disease (Central Nervous System) pipeline landscape. Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as the neuronal ceroid lipofuscinoses. Symptoms of Batten disease usually......
  • Trigeminal Neuralgia - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 54
    Trigeminal Neuralgia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Trigeminal Neuralgia - Pipeline Review, H2 2017, provides an overview of the Trigeminal Neuralgia (Central Nervous System) pipeline landscape. Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. Symptoms include spontaneous attacks of pain o......
  • Visceral Pain - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 55
    Visceral Pain - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Visceral Pain - Pipeline Review, H2 2017, provides an overview of the Visceral Pain (Central Nervous System) pipeline landscape. Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or NSAIDs and pai......
  • Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 119
    Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017, provides an overview of the Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline landscape. Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important c......
  • Liver Cirrhosis - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 90
    Liver Cirrhosis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H2 2017, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape. Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver wh......
  • Global Peptide Therapeutics Sales Market Report 2017
    Published: 14-Aug-2017        Price: US 4000 Onwards        Pages: 101
    In this report, the global Peptide Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Peptide Therapeutics for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs